Blue Earth Diagnostics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Blue Earth Diagnostics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 7 completed later-stage tilt top decile by trial count

Blue Earth Diagnostics: 9 sponsored US clinical trials, 1 recruiting.

Blue Earth Diagnostics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Invasive Lobular Breast Carcinoma, with 1 trials.

Top-decile sponsor footprint

Blue Earth Diagnostics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 1

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633
NOT YET RECRUITING Phase 4

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
COMPLETED Phase 4

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

NCT06604442
COMPLETED Phase 3

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133
COMPLETED Phase 2

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

NCT04410367
COMPLETED Phase 3

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

NCT04186845
COMPLETED Phase 3

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

NCT04186819
COMPLETED Phase 3

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

NCT02680041
COMPLETED

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

NCT02443571

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 4
Phase 4 2

Therapeutic Areas

Invasive Lobular Breast Carcinoma 1
Prostatic Neoplasms 1
Gastric Cancer 1
Pancreatic Ductal Adenocarcinoma 1
Colorectal Cancer 1
Prostate Cancer 1
Epithelial Ovarian Cancer 1

Where Blue Earth Diagnostics enrollment is open (later-stage tilt)

1 recruiting of 9 indexed (11% open); 7 completed (78%).

Phase mix: 6 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Invasive Lobular Breast Carcinoma (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Blue Earth Diagnostics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Blue Earth Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Blue Earth Diagnostics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Blue Earth Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Blue Earth Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Blue Earth Diagnostics page

9 registered trials is a research-attention snapshot, not an endorsement of Blue Earth Diagnostics or any single study.

  • 1 of Blue Earth Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Invasive Lobular Breast Carcinoma is the condition Blue Earth Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Invasive Lobular Breast Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Blue Earth Diagnostics pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.